ACAD logo

ACAD
Acadia Pharmaceuticals Inc

13,064
Mkt Cap
$3.76B
Volume
1.45M
52W High
$28.35
52W Low
$14.45
PE Ratio
9.59
ACAD Fundamentals
Price
$21.95
Prev Close
$22.45
Open
$22.31
50D MA
$22.19
Beta
0.97
Avg. Volume
1.71M
EPS (Annual)
$2.30
P/B
3.05
Rev/Employee
$1.34M
$3,771.04
Loading...
Loading...
News
all
press releases
Guardian Pharmacy Services to Report Q1 Earnings: What's in the Cards?
GRDN heads into Q1 earnings with revenues seen at $329.7M, as growth trends, vaccine volumes and IRA pricing impacts take center stage.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the planned retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development. Dr. Thompson has decided to retire for personal...
Business Wire·3d ago
News Placeholder
CSLLY vs. ACAD: Which Stock Is the Better Value Option?
CSLLY vs. ACAD: Which Stock Is the Better Value Option?
Zacks·3d ago
News Placeholder
Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3d ago
News Placeholder
Pictet Asset Management Holding SA Buys 84,055 Shares of ACADIA Pharmaceuticals Inc. $ACAD
Pictet Asset Management Holding SA grew its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 5.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,547,103 shares of the biopha...
MarketBeat·3d ago
News Placeholder
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·4d ago
News Placeholder
ACADIA Pharmaceuticals (ACAD) to Release Earnings on Wednesday
ACADIA Pharmaceuticals (NASDAQ:ACAD) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-acadia-pharmaceuticals-inc-stock...
MarketBeat·4d ago
News Placeholder
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: BofA Securities 2026 Health Care Conference Fireside Chat: Tuesday, May 12...
Business Wire·5d ago
News Placeholder
Axecap Investments LLC Has $3.65 Million Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD
Axecap Investments LLC decreased its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 32.8% in the 4th quarter, according to its most recent filing with the Securities...
MarketBeat·7d ago
News Placeholder
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from Brokerages
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twenty analysts that are currently covering the firm, MarketBeat reports...
MarketBeat·12d ago
<
1
2
...
>

Latest ACAD News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.